公开(公告)号：US11136401B2

公开(公告)日：2021-10-05

申请号：US15561967

申请日：2016-03-25

申请人： University of Southern California

发明人： Alan L. Epstein ,  Peisheng Hu ,  Jacek K. Pinski

IPC分类号： C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  A61K35/12 ,  A61K39/00 ,  G01N33/76

摘要： Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.

公开(公告)号：US11136392B2

公开(公告)日：2021-10-05

申请号：US15849107

申请日：2017-12-20

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

发明人： Renier J. Brentjens ,  Hollie Jaine Jackson ,  Cheng Liu

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K35/17 ,  A61K48/00 ,  C07K14/705 ,  C07K14/725 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  A61K39/00 ,  A61K38/00 ,  A61K35/12

摘要： The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.

公开(公告)号：US20210299185A1

公开(公告)日：2021-09-30

申请号：US17344205

申请日：2021-06-10

申请人： ABT Holding Company ,  AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Robert W. MAYS ,  Robert J. DEANS ,  David C. HESS ,  James E. CARROLL ,  Cesar V. BORLONGAN

IPC分类号： A61K35/50 ,  A61K35/545 ,  A61K38/13 ,  A61K45/06 ,  C12N5/074 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/485 ,  A61K31/52 ,  A61K31/661 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  A61K35/407 ,  A61K35/44 ,  A61K35/48 ,  A61K35/51

摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

公开(公告)号：US11129849B2

公开(公告)日：2021-09-28

申请号：US16291477

申请日：2019-03-04

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Samuel Strober ,  Robert Lowsky

IPC分类号： A61K35/28 ,  A61K35/12 ,  A61K35/22 ,  A61K35/14 ,  A61K38/19 ,  A61K41/00 ,  A61K45/06 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K38/13 ,  A61K39/00 ,  A61K39/395 ,  A61N5/10 ,  A61K35/17

摘要： Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

公开(公告)号：US11124769B2

公开(公告)日：2021-09-21

申请号：US15898526

申请日：2018-02-17

申请人： BOSTON MEDICAL CENTER CORPORATION ,  TRUSTEES OF BOSTON UNIVERSITY

发明人： George J. Murphy ,  David H. Sherr ,  Sarah S. Rozelle ,  Brenden W. Smith

IPC分类号： A61K35/19 ,  A61K31/404 ,  C12N5/0789 ,  C12N5/078 ,  A61K35/18 ,  G01N33/50 ,  A61K45/06 ,  A61K31/655 ,  G01N33/80 ,  G01N33/86 ,  A61K35/12

摘要： This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs, among other things.

公开(公告)号：US20210283187A1

公开(公告)日：2021-09-16

申请号：US17141327

申请日：2021-01-05

申请人： SALK INSTITUTE FOR BIOLOGICAL STUDIES

发明人： RONALD M. EVANS ,  EIJI YOSHIHARA ,  MICHAEL R. DOWNES ,  RUTH T. YU ,  ANNETTE R. ATKINS

IPC分类号： A61K35/39 ,  C12N5/071 ,  C07K14/705 ,  C07K14/72 ,  A61K48/00 ,  A61K35/12 ,  A61K35/35 ,  A61K35/51 ,  A61K35/545 ,  C12N15/85 ,  C12N15/86

摘要： The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.

公开(公告)号：US11116794B2

公开(公告)日：2021-09-14

申请号：US16291492

申请日：2019-03-04

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Samuel Strober ,  Robert Lowsky

IPC分类号： A61K35/12 ,  A61K35/28 ,  A61K35/22 ,  A61K35/14 ,  A61K38/19 ,  A61K41/00 ,  A61K45/06 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K38/13 ,  A61K39/00 ,  A61K39/395 ,  A61N5/10 ,  A61K35/17

摘要： Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

公开(公告)号：US11111481B2

公开(公告)日：2021-09-07

申请号：US15764691

申请日：2016-09-29

申请人： RAMOT AT TEL-AVIV UNIVERSITY LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  SYNVACCINE LTD.

发明人： Tamir Tuller ,  Eli Goz ,  Shimshi Atar ,  Hadas Zur

IPC分类号： C12N7/00 ,  C12N7/04 ,  A61K35/76 ,  A61K35/12 ,  G16B99/00 ,  A61K39/12 ,  A61K39/00

摘要： Attenuated viruses and methods of designing them are disclosed. In one embodiment, there is disclosed an attenuated form of a virulent virus comprising an RNA encoding a viral protein or a nucleic acid sequence transcribable to said RNA, wherein the folding energy or structure of the RNA is changed at positions of evolutionarily conserved RNA structures with respect to that of said RNA encoding said viral protein in the virulent virus so as to bring about attenuation of the virus.

公开(公告)号：US11111475B2

公开(公告)日：2021-09-07

申请号：US16414576

申请日：2019-05-16

申请人： University of Georgia Research Foundation, Inc. ,  Aruna Bio, Inc.

发明人： Steven L. Stice ,  Robin Lynn Webb ,  Tracy A. Stice

IPC分类号： A61K35/12 ,  A61K35/30 ,  A61K35/545 ,  C12N5/0793 ,  C12N5/079 ,  A61P25/28 ,  G01N33/569

摘要： Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.

公开(公告)号：US20210269765A1

公开(公告)日：2021-09-02

申请号：US17126942

申请日：2020-12-18

申请人： Industrial Technology Research Institute

发明人： Chia-Jung LU ,  Jing-En HUANG ,  Liang-Cheng SU ,  Hsin-Hsin SHEN ,  Yuchi WANG ,  Ying-Hsueh CHAO ,  Li-Hsin LIN ,  Hsiu-Hua HUANG

IPC分类号： C12N5/00 ,  A61K35/12 ,  A61K9/00 ,  A61K47/38 ,  A61K47/42

摘要： A temperature-sensitive cell culture composition is provided. The temperature-sensitive cell culture composition includes a hydrogel, a cellulose, a gelatin and a collagen. Based on 1 part by weight of the collagen, a content of the hydrogel is between 0.03 parts by weight and 60 parts by weight, a content of the cellulose is between 150 parts by weight and 360 parts by weight, and a content of the gelatin is between 21 parts by weight and 12 parts by weight. In addition, a method for using the temperature-sensitive cell culture composition, a method for forming the temperature-sensitive cell culture composition, and a use of the temperature-sensitive cell culture composition are also provided.